Epidemiology: Arthritis more common than expected

Comment

Jessica McHugh. Nat Rev Rheumatol. 2017.

. 2017 Dec 19;14(1):3.

doi: 10.1038/nrrheum.2017.203.

No abstract available

Comment on

Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors.
Gladman D, Rigby W, Azevedo VF, Behrens F, Blanco R, Kaszuba A, Kudlacz E, Wang C, Menon S, Hendrikx T, Kanik KS. Gladman D, et al. N Engl J Med. 2017 Oct 19;377(16):1525-1536. doi: 10.1056/NEJMoa1615977. N Engl J Med. 2017. PMID: 29045207 Clinical Trial.
Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis.
Mease P, Hall S, FitzGerald O, van der Heijde D, Merola JF, Avila-Zapata F, Cieślak D, Graham D, Wang C, Menon S, Hendrikx T, Kanik KS. Mease P, et al. N Engl J Med. 2017 Oct 19;377(16):1537-1550. doi: 10.1056/NEJMoa1615975. N Engl J Med. 2017. PMID: 29045212 Clinical Trial.
Updated Estimates Suggest a Much Higher Prevalence of Arthritis in United States Adults Than Previous Ones.
Jafarzadeh SR, Felson DT. Jafarzadeh SR, et al. Arthritis Rheumatol. 2018 Feb;70(2):185-192. doi: 10.1002/art.40355. Epub 2018 Jan 3. Arthritis Rheumatol. 2018. PMID: 29178176 Free PMC article.